Wallace Akerley

27.3k total citations
156 papers, 5.2k citations indexed

About

Wallace Akerley is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Wallace Akerley has authored 156 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 107 papers in Pulmonary and Respiratory Medicine, 104 papers in Oncology and 25 papers in Molecular Biology. Recurrent topics in Wallace Akerley's work include Lung Cancer Treatments and Mutations (82 papers), Lung Cancer Research Studies (37 papers) and Lung Cancer Diagnosis and Treatment (34 papers). Wallace Akerley is often cited by papers focused on Lung Cancer Treatments and Mutations (82 papers), Lung Cancer Research Studies (37 papers) and Lung Cancer Diagnosis and Treatment (34 papers). Wallace Akerley collaborates with scholars based in United States, Italy and Germany. Wallace Akerley's co-authors include Howard Safran, Bernard F. Cole, William W. Mayo-Smith, Damian E. Dupuy, Peter V. Kavanagh, Ronald J. Zagoria, Michael Glantz, H. Choy, Joachim von Pawel and James E. Herndon and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Wallace Akerley

149 papers receiving 5.0k citations

Peers

Countries citing papers authored by Wallace Akerley

Since Specialization

Citations

This map shows the geographic impact of Wallace Akerley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wallace Akerley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wallace Akerley more than expected).

Fields of papers citing papers by Wallace Akerley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wallace Akerley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wallace Akerley. The network helps show where Wallace Akerley may publish in the future.

Co-authorship network of co-authors of Wallace Akerley

This figure shows the co-authorship network connecting the top 25 collaborators of Wallace Akerley. A scholar is included among the top collaborators of Wallace Akerley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wallace Akerley. Wallace Akerley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042) 2023 ·Clinical Cancer Research ·Shirish M. Gadgeel, Jieling Miao, Jonathan W. Riess, (unknown), Philip C. Mack, Gregory J. Gerstner, Timothy F. Burns, (unknown), Wallace Akerley, Konstantin H. Dragnev, Noel Laudi, Mary W. Redman, Jhanelle E. Gray, David R. Gandara, Karen Kelly	9
2	Real-world comparison of survival outcomes with cisplatin versus carboplatin in patients with limited-stage small-cell lung cancer 2023 ·Cancer Treatment and Research Communications ·(unknown), (unknown), Jennifer A. Sinnott, Sonam Puri, Wallace Akerley, Benjamin Haaland, Shiven B. Patel	3
3	A rare FGF5 candidate variant (rs112475347) for predisposition to nonsquamous, nonsmall‐cell lung cancer 2023 ·International Journal of Cancer ·Lisa Cannon‐Albright, Craig C. Teerlink, Jeff Stevens, Julio C. Facelli, Shamus R. Carr, Kristina Allen‐Brady, Sonam Puri, Joan E. Bailey‐Wilson, Anthony M. Musolf, Wallace Akerley	1
4	Abstract 1125: Neoantigen immunogenicity landscapes and evolution of tumor ecosystems during immunotherapy with nivolumab 2023 ·Cancer Research ·Tyler Alban, Nadeem Riaz, (unknown), Vlad Makarov, (unknown), Seong‐Keun Yoo, Rachna Shah, Nils Weinhold, Raghvendra M. Srivastava, Xiaoxiao Ma, Chirag Krishna, Edward B. Garon, Wallace Akerley, Ben Creelan, (unknown), Diego Chowell, William J. Geese, Naiyer A. Rizvi, Timothy A. Chan	1
5	Pathways to lung cancer diagnosis among individuals who did not receive lung cancer screening: a qualitative study 2023 ·BMC Primary Care ·(unknown), Mollie E. Barnard, (unknown), (unknown), (unknown), (unknown), (unknown), Wallace Akerley, Melissa H. Watt, Jennifer A. Doherty, (unknown)	4
6	Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study 2020 ·JTO Clinical and Research Reports ·James Chih‐Hsin Yang, Karen L. Reckamp, Young‐Chul Kim, Silvia Novello, Egbert F. Smit, Jong-Seok Lee, Wu‐Chou Su, Wallace Akerley, Collin M. Blakely, Harry J.M. Groen, Lyudmila Bazhenova, Enric Carcereny, Rita Chiari, Te‐Chun Hsia, Tony Golsorkhi, Darrin Despain, Danny Shih, Sanjay Popat, Heather A. Wakelee	19
7	Public awareness and perceptions surrounding radon testing in a state with high radon emission potential and low smoking rates. 2019 ·Journal of environmental health ·(unknown), (unknown), (unknown), Wallace Akerley, L. M. V. Martel, G Harding, (unknown), Anne C. Kirchhoff, Deanna Kepka	5
8	Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC 2018 ·PLoS ONE ·Michael E. Goldberg, Meagan Montesion, Lauren Young, James Suh, Joel Greenbowe, Mark Kennedy, Giuseppe Giaccone, Wallace Akerley, Afshin Dowlati, Ben Creelan, J. Kevin Hicks, Paul J. Hesketh, Karen Kelly, Jonathan W. Riess, Vincent A. Miller, Philip J. Stephens, Garrett M. Frampton, Siraj M. Ali, Jeffrey P. Gregg, Lee A. Albacker	15
9	Adverse Event Management in Patients with BRAF V600E-Mutant Non-Small Cell Lung Cancer Treated with Dabrafenib plus Trametinib 2018 ·The Oncologist ·A. Chalmers, (unknown), Wallace Akerley	19
10	Phase Ib KEYNOTE-200: A study of an intravenously delivered oncolytic virus, coxsackievirus A21 in combination with pembrolizumab in advanced NSCLC and bladder cancer patients 2018 ·Annals of Oncology ·Charles M. Rudin, Hardev Pandha, Sumati Gupta, Matthew R. Zibelman, Wallace Akerley, Daphne Day, Andrew Hill, Rachel E. Sanborn, Steven O’Day, Timothy Clay, Gavin Wright, Ross Jennens, David E. Gerber, Jonathan E. Rosenberg, Christy Ralph, David C. Campbell, Brendan D. Curti, Emmett V. Schmidt, Mark Grose, Darren R. Shafren	15
11	Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR-Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study 2017 ·Journal of Thoracic Oncology ·Giorgio V. Scagliotti, Dale E. Shuster, С. В. Орлов, Joachim von Pawel, Frances A. Shepherd, Jeffrey S. Ross, (unknown), Brian Schwartz, Wallace Akerley	37
12	Weekly, high‐dose paclitaxel in advanced lung carcinoma 2003 ·Cancer ·Wallace Akerley, James E. Herndon, Merrill J. Egorin, Alan P. Lyss, Hedy L. Kindler, (unknown), Carol A. Sherman, David Rosen, Donna Hollis, Mark J. Ratain, Mark R. Green	54
13	Treatment of the jaundiced patient with breast carcinoma 2001 ·Cancer ·Irina Gurevich, Wallace Akerley	5
14	Treatment of the jaundiced patient with breast carcinoma 2001 ·Cancer ·Irina Gurevich, Wallace Akerley	1
15	Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. 1998 ·Journal of Clinical Oncology ·H. Choy, Wallace Akerley, Howard Safran, Stephen L. Graziano, Christine H. Chung, Todd Williams, Bernard F. Cole, T. Kennedy	190
16	Prostate-Specific Antigen Response to Withdrawal of Megestrol Acetate in a Patient With Hormone-Refractory Prostate Cancer 1997 ·Mayo Clinic Proceedings ·(unknown), Barry S. Stein, Wallace Akerley	1
17	Prostate-Specific Antigen Response to Withdrawal of Megestrol Acetate in a Patient With Hormone-Refractory Prostate Cancer 1997 ·Mayo Clinic Proceedings ·(unknown), (unknown), Wallace Akerley	9
18	Weekly high-dose paclitaxel in metastatic and locally advanced breast cancer: a preliminary report. 1997 ·PubMed ·Wallace Akerley, (unknown), F J Cummings, Howard Safran, Rochelle Strenger, Douglas J. Marchant	28
19	Weekly paclitaxel with and without concurrent radiation therapy: Toxicity, pharmacokinetics, and response 1997 ·Seminars in Radiation Oncology ·Michael Glantz, H. Choy, Wallace Akerley, Christine M. Kearns, Merrill J. Egorin, C. Harker Rhodes, Bernard F. Cole	7
20	Concurrent Paclitaxel and Radiation Therapy for Solid Tumors 1996 ·Cancer Control ·H. Choy, Wallace Akerley, Michael Glantz, Howard Safran, Stephen L. Graziano, (unknown)	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact